bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
187 hedge funds and large institutions have $182M invested in bluebird bio in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 64 increasing their positions, 39 reducing their positions, and 32 closing their positions.
69% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 32
64% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 39
11% more funds holding
Funds holding: 168 → 187 (+19)
1.83% more ownership
Funds ownership: 4.19% → 6.02% (+1.8%)
3% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $5.25M
33% less capital invested
Capital invested by funds: $273M → $182M (-$90.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$21.1M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$12.1M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$10.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.63M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$9.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.87M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$7.6M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$6.79M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.23M |
BLUE Hedge Fund Activity: Q4 2023 in Review
187 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2023, worth a combined $182M — down 33% from $273M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new BLUE positions and 32 closed out — a net gain of 22 holders — while 64 added to existing stakes and 39 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $21.1M. The largest seller was PFM Health Sciences, cutting an estimated $12.2M.
- 187 institutional investors held bluebird bio (BLUE) as of Q4 2023, up from 168 in Q3 2023.
- Funds reported $182M of bluebird bio stock for Q4 2023, down 33% quarter-over-quarter.
- 54 funds opened new bluebird bio positions in Q4 2023 and 32 closed out, a net change of +22 holders.
- The largest bluebird bio buyer in Q4 2023 was Alyeska Investment Group, an estimated $21.1M added.
- The largest bluebird bio seller in Q4 2023 was PFM Health Sciences, an estimated $12.2M sold.
Based on aggregated 13F filings for Q4 2023.